喜讯!罗氏的Tecentriq在中国获得批准,用于治疗广泛期小细胞肺癌

2020-02-15 Allan MedSci原创

罗氏制药公司近日宣布,经中国国家药品监督管理局(NMPA)批准,Tecentriq(atezolizumab)与化疗联合可用于广泛期小细胞肺癌(SCLC)患者的一线治疗,Tecentriq(atezolizumab)是针对程序性细胞死亡配体1(PD-L1)的IgG1抗体。

罗氏制药公司近日宣布,经中国国家药品监督管理局(NMPA)批准,Tecentriqatezolizumab)与化疗联合可用于广泛期小细胞肺癌SCLC)患者的一线治疗,Tecentriqatezolizumab)是针对程序性细胞死亡配体1PD-L1)的IgG1抗体。罗氏全球产品开发负责人Levi Garraway称:“Tecentriq在美国FDA和欧洲EMA批准后不到一年的时间内,就在中国获得批准用于广泛期SCLC的初始治疗

在中国,抑制PD-L1的药物也正在与阿瓦斯汀(贝伐单抗)联合使用,以治疗尚未接受过全身治疗的无法切除的肝细胞癌患者。根据罗氏的说法,在中国进行的IIIIMpower133研究的结果表明,与单独化疗相比,Tecentriq联合化疗可以使患者的寿命大大延长。此外,将Tecentriq和化学疗法联合使用可使无进展生存期(PFS)达到5.2个月,这明显长于比较组的4.3个月。


原始出处:

https://www.firstwordpharma.com/node/1700775

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1811413, encodeId=f15b1811413de, content=<a href='/topic/show?id=26ae8803219' target=_blank style='color:#2F92EE;'>#获得批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88032, encryptionId=26ae8803219, topicName=获得批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=838d2500169, createdName=12498cb5m13暂无昵称, createdTime=Fri Oct 30 02:37:00 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652401, encodeId=0b4616524011b, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Fri Aug 07 21:37:00 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350169, encodeId=d460135016988, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49172, encryptionId=3e7f491e23e, topicName=广泛期小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Feb 17 07:37:00 CST 2020, time=2020-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509586, encodeId=f38e1509586cd, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17246, encryptionId=b2bd1e246ab, topicName=Tecentriq)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2d810099674, createdName=lfyang, createdTime=Mon Feb 17 07:37:00 CST 2020, time=2020-02-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1811413, encodeId=f15b1811413de, content=<a href='/topic/show?id=26ae8803219' target=_blank style='color:#2F92EE;'>#获得批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88032, encryptionId=26ae8803219, topicName=获得批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=838d2500169, createdName=12498cb5m13暂无昵称, createdTime=Fri Oct 30 02:37:00 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652401, encodeId=0b4616524011b, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Fri Aug 07 21:37:00 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350169, encodeId=d460135016988, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49172, encryptionId=3e7f491e23e, topicName=广泛期小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Feb 17 07:37:00 CST 2020, time=2020-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509586, encodeId=f38e1509586cd, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17246, encryptionId=b2bd1e246ab, topicName=Tecentriq)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2d810099674, createdName=lfyang, createdTime=Mon Feb 17 07:37:00 CST 2020, time=2020-02-17, status=1, ipAttribution=)]
    2020-08-07 shock_melon
  3. [GetPortalCommentsPageByObjectIdResponse(id=1811413, encodeId=f15b1811413de, content=<a href='/topic/show?id=26ae8803219' target=_blank style='color:#2F92EE;'>#获得批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88032, encryptionId=26ae8803219, topicName=获得批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=838d2500169, createdName=12498cb5m13暂无昵称, createdTime=Fri Oct 30 02:37:00 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652401, encodeId=0b4616524011b, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Fri Aug 07 21:37:00 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350169, encodeId=d460135016988, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49172, encryptionId=3e7f491e23e, topicName=广泛期小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Feb 17 07:37:00 CST 2020, time=2020-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509586, encodeId=f38e1509586cd, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17246, encryptionId=b2bd1e246ab, topicName=Tecentriq)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2d810099674, createdName=lfyang, createdTime=Mon Feb 17 07:37:00 CST 2020, time=2020-02-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1811413, encodeId=f15b1811413de, content=<a href='/topic/show?id=26ae8803219' target=_blank style='color:#2F92EE;'>#获得批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88032, encryptionId=26ae8803219, topicName=获得批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=838d2500169, createdName=12498cb5m13暂无昵称, createdTime=Fri Oct 30 02:37:00 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652401, encodeId=0b4616524011b, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Fri Aug 07 21:37:00 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350169, encodeId=d460135016988, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49172, encryptionId=3e7f491e23e, topicName=广泛期小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Feb 17 07:37:00 CST 2020, time=2020-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509586, encodeId=f38e1509586cd, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17246, encryptionId=b2bd1e246ab, topicName=Tecentriq)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2d810099674, createdName=lfyang, createdTime=Mon Feb 17 07:37:00 CST 2020, time=2020-02-17, status=1, ipAttribution=)]
    2020-02-17 lfyang

相关资讯

因价格问题,NICE拒绝将罗氏的PD-L1单抗Tecentriq联合化疗用于广泛期小细胞肺癌

英国国家健康与护理卓越研究所(NICE)已发布指南草案,拒绝将罗氏的PD-L1单抗Tecentriq(atezolizumab)与卡铂和依托泊苷联合用于成人未经治疗的广泛期小细胞肺癌(SCLC)患者。该机构表示,虽然PD-L1抑制剂"符合NICE的标准,治疗可以延长患者的寿命的……但Tecentriq联合化疗的成本效益估算值高于NHS可接受的额度。"